IGHE and allergic disease: Beyond omalizumab and ligelizumab, several other attempts at developing improved anti-IgE biologics (e.g., UB-221, 8D6, MeDI4212) for treatment of various allergic diseases have also been made but have yet to reach late-stage clinical trials (137–139).